{"id":48893,"date":"2022-09-28T02:01:39","date_gmt":"2022-09-28T00:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/"},"modified":"2022-09-28T02:01:39","modified_gmt":"2022-09-28T00:01:39","slug":"biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/","title":{"rendered":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress"},"content":{"rendered":"<div>\n<p>BEIJING&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ADC?src=hash\" target=\"_blank\" rel=\"noopener\">#ADC<\/a>&#8211;Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;, HKEX: 02315) will host <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbiojapan2022.jcdbizmatch.jp%2FLookup%2Fen%2FSeminar%2Fu0%3Fke%3Dbiocytogen%26np%3D2%26ob%3D5&amp;esheet=52927244&amp;newsitemid=20220928005077&amp;lan=en-US&amp;anchor=a+seminar&amp;index=1&amp;md5=906c30964d52dd0aa74c11083aa2c194\" rel=\"nofollow noopener\" shape=\"rect\">a seminar<\/a> at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/5\/Biocytogen%27s_LOGO.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFive RenMice<sup>TM<\/sup>-based fully human antibody discovery platforms: RenMab<sup>TM<\/sup>-based monoclonal antibody platform, RenLite<sup>\u00ae<\/sup>-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform\n<\/li>\n<li>\nProgress of Project Integrum, a large-scale project to develop antibody therapeutics for 1000+ targets by deploying <i>in vivo<\/i> evidence-based high-throughput screening\n<\/li>\n<li>\nLeading bispecific ADC assets targeting HER2 x TROP2 (YH012) and EGFR x c-MET (YH013)\n<\/li>\n<li>\nPhase I results of YH003, an agonistic CD40 monoclonal antibody in an ongoing phase II multi-regional clinical trial in unresectable\/metastatic PDAC patients\n<\/li>\n<\/ul>\n<p>\nThe seminar will begin with an overview of Biocytogen\u2019s therapeutic antibody discovery technology platforms and preclinical\/clinical assets provided by Dr. Vivian Tian, including YH003, TNFR2, B7H3, CCR8, Siglec-15, and CTLA-4 x OX40 bispecific antibody (YH006). Dr. Jie Xiang will outline the company\u2019s Project Integrum and antibody discovery capabilities at Biocytogen, including innovative animal models and preclinical pharmacology platform. Finally, Dr. Yanan Guo will introduce the company\u2019s RenLite<sup>\u00ae<\/sup> mouse and bispecific ADC platform.\n<\/p>\n<p>\nBiocytogen\u2019s business development team will attend the conference and set up a booth (B-45). Please click to <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbiojapan2022.jcdbizmatch.jp%2Fen%2FLogin&amp;esheet=52927244&amp;newsitemid=20220928005077&amp;lan=en-US&amp;anchor=reserve+a+1-on-1+partnering+meeting+with+us&amp;index=2&amp;md5=dce127c9da91a827a004df396d1cd2ae\" rel=\"nofollow noopener\" shape=\"rect\">reserve a 1-on-1 partnering meeting with us<\/a>. We look forward to seeing you on site or online! Any questions, please contact us at <a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o&#58;&#66;&#x44;&#x2d;&#x4c;i&#99;&#101;&#x6e;&#x73;in&#103;&#x40;&#x62;&#x69;o&#99;&#121;&#x74;&#x6f;ge&#110;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#66;&#x44;&#45;&#x4c;i&#99;&#x65;&#110;&#x73;i&#x6e;g&#64;&#x62;&#105;&#x6f;c&#x79;&#x74;&#111;&#x67;e&#x6e;&#46;&#99;&#x6f;&#109;<\/a>.\n<\/p>\n<p>\n<b>About Biocytogen<\/b>\n<\/p>\n<p>\nBiocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frenmab.com&amp;esheet=52927244&amp;newsitemid=20220928005077&amp;lan=en-US&amp;anchor=RenMabTM+%2FRenLite%26%23174%3B+mice+platforms&amp;index=3&amp;md5=c8f11c4413c6b185731bd0cb51292b04\" rel=\"nofollow noopener\" shape=\"rect\">RenMab<sup>TM<\/sup> \/RenLite<sup>\u00ae<\/sup> mice platforms<\/a> for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fen.biocytogen.com.cn%2Fko-library.html&amp;esheet=52927244&amp;newsitemid=20220928005077&amp;lan=en-US&amp;anchor=Project+Integrum&amp;index=4&amp;md5=b9bd3cb4f760761a3e3f7f39e2511cfc\" rel=\"nofollow noopener\" shape=\"rect\">Project Integrum<\/a>, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and\/or best-in-class antibody drugs. The company&#8217;s pipeline includes 12 core assets among which two are in phase II multi-regional clinical trials and two are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fen.biocytogen.com.cn&amp;esheet=52927244&amp;newsitemid=20220928005077&amp;lan=en-US&amp;anchor=http%3A%2F%2Fen.biocytogen.com.cn&amp;index=5&amp;md5=b0f7de5a722d505922af1493027bdf60\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/en.biocytogen.com.cn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Biocytogen<\/b><br \/>Platform and Assets: <a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x42;D&#45;&#x4c;&#105;&#x63;&#101;&#x6e;s&#x69;n&#103;&#x40;&#98;&#x69;&#111;&#x63;&#121;&#x74;o&#x67;e&#110;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#66;&#x44;-&#x4c;&#x69;&#99;&#x65;n&#x73;&#x69;&#110;&#x67;&#64;&#x62;&#x69;&#111;&#x63;y&#x74;&#x6f;&#103;&#x65;n&#x2e;&#x63;&#111;&#x6d;<\/a><br \/>Media: <a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#111;&#58;&#112;&#114;&#64;bb&#x63;&#x74;&#x67;&#x2e;&#x63;&#x6f;&#109;&#46;&#99;n\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x40;&#98;b&#x63;&#116;&#x67;&#x2e;c&#x6f;&#109;&#46;&#x63;&#110;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING&#8211;(BUSINESS WIRE)&#8211;#ADC&#8211;Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite\u00ae-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform Progress of Project &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48893","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING&#8211;(BUSINESS WIRE)&#8211;#ADC&#8211;Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite\u00ae-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform Progress of Project ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T00:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress\",\"datePublished\":\"2022-09-28T00:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/\"},\"wordCount\":410,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005077\\\/en\\\/1583735\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/\",\"name\":\"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005077\\\/en\\\/1583735\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"datePublished\":\"2022-09-28T00:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005077\\\/en\\\/1583735\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005077\\\/en\\\/1583735\\\/21\\\/Biocytogen%27s_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend","og_description":"BEIJING&#8211;(BUSINESS WIRE)&#8211;#ADC&#8211;Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite\u00ae-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform Progress of Project ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-28T00:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress","datePublished":"2022-09-28T00:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/"},"wordCount":410,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/","name":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg","datePublished":"2022-09-28T00:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928005077\/en\/1583735\/21\/Biocytogen%27s_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-to-present-at-biojapan2022-introducing-innovative-rd-platforms-bispecific-adc-programs-and-pipeline-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen to Present at BioJapan2022, Introducing Innovative R&amp;D Platforms, Bispecific ADC Programs and Pipeline Progress"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48893"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48893\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}